Cipla falls as USFDA issues 5 inspectional observations to New York facility of company’s arm

21 Sep 2023 Evaluate

Cipla is currently trading at Rs. 1216.10, down by 22.75 points or 1.84% from its previous closing of Rs. 1238.85 on the BSE.

The scrip opened at Rs. 1231.05 and has touched a high and low of Rs. 1240.00 and Rs. 1210.30 respectively. So far 22416 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023.

Last one week high and low of the scrip stood at Rs. 1257.60 and Rs. 1210.30 respectively. The current market cap of the company is Rs. 97984.12 crore.

The promoters holding in the company stood at 33.47%, while Institutions and Non-Institutions held 49.76% and 16.77% respectively.

United States Food and Drug Administration (USFDA) has concluded inspection at Cipla’s wholly owned subsidiary -- InvaGen Pharmaceuticals’ manufacturing facility located in Central Islip, Long Island, New York, USA. The said inspection conducted from September 11, 2023 to September 19, 2023. The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI) for a site transfer product within InvaGen.

On conclusion of the inspection, InvaGen has received 5 inspectional observations in Form 483. There are no repeat or data integrity (DI) observations. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1475.90 -0.55 (-0.04%)
24-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1817.60
Dr. Reddys Lab 1351.25
Cipla 1475.90
Lupin 2168.30
Zydus Lifesciences 964.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.